Arkin Bio is an activity of Arkin Capital, a multi-billion-dollar VC, PE and Hedge Funds manager, targeting both early-stage and late-stage investments in Israel and around the world. They strategically invest through four main arms – Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate – covering 10 core investment activities and eight dedicated funds. Arkin Bio Ventures identifies, invests in, and accompanies innovative early and mid-stage companies with game-changing breakthroughs in areas such as immunotherapy, cancer, metabolism, microbiome, central nervous system, autoimmune diseases, orphan diseases, and drug-delivery platforms. Arkin Bio Ventures' management team leads and supports its portfolio companies through the hurdles of drug development, towards the proof-of-concept stage and beyond, to significant value creation. Arkin Bio Ventures is currently invested in companies in various stages of product development. Arkin Bio Ventures is a joint venture between insurance and finance company Phoenix Group (49%) and Arkin Holdings (51%). In 2016, the two companies announced a strategic collaboration agreement for investment in pharmaceutical and biotechnology companies, for a total of approximately $60 million (with an option to increase the investment in the future).